Adicet Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $87.3M
- Price
- $9.11
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.23%
- Volume
- 101.4K
About
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Quick stats
Shares outstanding9.6M
Computed float8.3M
Float / shares86.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001720580
Websitehttps://www.adicetbio.com
AI Summary
AI-generated1/16
minorneutralearnings
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio reported a Q2 net loss of $21.4 million, or $1.99 per share, with cash, cash equivalents, and short-term investments totaling $118.2 million as of June 30, 2026.
The company confirmed that its current capital resources are sufficient to fund operating expenses into the second half of 2027 while it advances its pipeline.
Operationally, a Phase 1 clinical update for prula-cel in lupus nephritis and SLE is anticipated in the third quarter of 2026, while a regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer is expected in the third quarter.
Red flags
- Interim Chief Medical Officer appointed following the departure of Dr. Julie Maltzman.